Organon & Co.

LSE:0A9W Stock Report

Market Cap: US$3.8b

Organon Future Growth

Future criteria checks 1/6

Organon's earnings are forecast to decline at 8.3% per annum while its annual revenue is expected to grow at 0.02% per year. EPS is expected to decline by 8.7% per annum. Return on equity is forecast to be 84.3% in 3 years.

Key information

-8.3%

Earnings growth rate

-8.7%

EPS growth rate

Pharmaceuticals earnings growth19.7%
Revenue growth rate0.02%
Future return on equity84.3%
Analyst coverage

Good

Last updated19 Dec 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

LSE:0A9W - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20266,5731,0011,1031,0786
12/31/20256,4948561,0339837
12/31/20246,4129157011,1296
9/30/20246,4091,301646946N/A
6/30/20246,3461,0007871,066N/A
3/31/20246,3471,047458761N/A
12/31/20236,2631,023538799N/A
9/30/20236,150585424669N/A
6/30/20236,168754320725N/A
3/31/20236,145746431849N/A
12/31/20226,174917431858N/A
9/30/20226,2921,011138638N/A
6/30/20226,3551,107343689N/A
3/31/20226,3651,3045641,077N/A
12/31/20216,3041,3511,9702,458N/A
9/30/20216,3141,5252,3702,841N/A
6/30/20216,3271,7622,3042,761N/A
3/31/20216,2581,9172,7723,025N/A
12/31/20206,5322,2561,9322,187N/A
12/31/20197,7773,3062,6752,767N/A
12/31/20189,7772,1533,5863,687N/A
12/31/201710,5001,801N/A3,419N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 0A9W's earnings are forecast to decline over the next 3 years (-8.3% per year).

Earnings vs Market: 0A9W's earnings are forecast to decline over the next 3 years (-8.3% per year).

High Growth Earnings: 0A9W's earnings are forecast to decline over the next 3 years.

Revenue vs Market: 0A9W's revenue (0.02% per year) is forecast to grow slower than the UK market (3.6% per year).

High Growth Revenue: 0A9W's revenue (0.02% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 0A9W's Return on Equity is forecast to be very high in 3 years time (84.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/26 02:15
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Organon & Co. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Balaji PrasadBarclays
Balaji PrasadBarclays
Navann Ty DietschiBNP Paribas Exane